AZ-UNIVERSAL-ELECTRONICS
1.5.2020 22:17:07 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control and sensing technologies for the smart home, has received five 2020 Red Dot Awards , one of the most prestigious international design awards, in the Product Design category. Products from UEI’s consumer brand, One For All , won four of the five awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200501005501/en/
The award-winning products were designed by UEI’s design team in the Netherlands, part of the global Designovation team which creates product designs based on user insights and innovative technology. Led by Rex Xu, Director of Design and User Experience, the team in the Netherlands works closely with UEI’s design offices in the U.S. and Hong Kong to ensure all products truly reflect global trends in design and technology.
“Winning five Red Dot Awards is a true honor and a testament to our design team’s exceptional talent,” said Xu. “Design is one of UEI’s key differentiators and we always create our designs with the user experience in mind. The team works under clear guiding principles of our successful Designovation formula which creates honest product designs based on true consumer insights applying the latest technology and design trends.”
Two of One For All’s TV stands were recognized with 2020 Red Dot Awards:
The Tripod Universal TV Stand fits televisions up to 65 inches, can swivel a true 360 degrees and blends into any corner with natural chestnut or oak wooden legs for a modern look.
The One For All Falcon Universal TV Stand supports televisions up to 70 inches and is designed to accommodate soundbars, streaming boxes and game consoles connected to the television. With its fabric skinned storage cover at the back of the television, cables are completely out of sight.
One For All also won two Red Dot awards for its market-leading digital TV antennas:
The Amplified Indoor TV Antenna features leading reception technology in a beautiful fabric skinned housing. With its homey design, it can hang on the wall, stand or lie flat while allowing for maximum channel coverage.
The darker colored Amplified Indoor TV Antenna offers a stylish look and unique signal level indicator that blends into the fabric housing. This ensures optimal signal and maximum number of available channels.
The fifth Red Dot Award is for UEI’s Kita premium Android TV voice remote control specifically designed for service providers with advanced video services that want a simplified user experience. In addition to supporting voice control and dedicated streaming app keys, this remote control features adaptive control which interacts with the television and only shows users the keys they need. It uses rechargeable technology in a slim housing, saving multiple batteries over the life of the product.
For more information about how to purchase these award-winning products, contact info@uei.com .
In 2019 One For All won Red Dot Awards for its Amplified Indoor Ball Design Antenna and One For All FLUX Gas Spring TV Wall Mount. With origins dating back to 1955, the Red Dot is established internationally as one of the most sought-after quality marks for outstanding design with annual competitions for Product Design, Brands and Communication, and Design Concept. Red Dot Award submissions are evaluated by a jury of independent designers, design professors and journalists.
All trademarks appearing herein are the property of their respective owners.
One For All is a registered trademark of Universal Electronics Inc.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, visit www.uei.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom